ライフサイエンスコーパス: peripheral artery disease

1 r disease (myocardial infarction, stroke, or peripheral artery disease).

2 ion functional class, wall motion score, and peripheral artery disease).

3 disease, ischemic stroke, heart failure, and peripheral artery disease).

4 eGFR] and albuminuria) with the incidence of peripheral artery disease.

5 in improving the outcomes for patients with peripheral artery disease.

6 of patients with symptomatic femoropopliteal peripheral artery disease.

7 pliteal lesions in symptomatic patients with peripheral artery disease.

8 t advance in the management of patients with peripheral artery disease.

9 athophysiology of the exercise impairment in peripheral artery disease.

10 l tool to investigate the pathophysiology of peripheral artery disease.

11 161 patients with AAA and 168 controls with peripheral artery disease.

12 low in the murine hindlimb ischemia model of peripheral artery disease.

13 to be underused among Medicare patients with peripheral artery disease.

14 dependently associated with the incidence of peripheral artery disease.

15 nd 2010 to estimate the global prevalence of peripheral artery disease.

16 ding 112,027 participants, of which 9347 had peripheral artery disease.

17 risk for stroke, venous thromboembolism and peripheral artery disease.

18 aseline clinical characteristics, except for peripheral artery disease.

19 re considered as biomarkers for coronary and peripheral artery disease.

20 ance than ST, even for those with aortoiliac peripheral artery disease.

21 ificantly reduced in PACs from patients with peripheral artery disease.

22 nanofibers improves blood flow in a model of peripheral artery disease.

23 ly similar to those displayed by humans with peripheral artery disease.

24 end point among this cohort of patients with peripheral artery disease.

25 ate a symptomatic benefit of this therapy in peripheral artery disease.

26 ak walking time in patients with symptomatic peripheral artery disease.

27 Aging is a risk factor for coronary and peripheral artery disease.

28 omplicated percutaneous revascularization of peripheral artery disease.

29 artery is common in patients suffering from peripheral artery disease.

30 disease is a risk factor for lower-extremity peripheral artery disease.

31 ction seen in rats with ligated arteries and peripheral artery disease.

32 potent antiplatelet agent, in patients with peripheral artery disease.

33 as nonhealing ulcers or gangrene, related to peripheral artery disease.

34 in skeletal muscle biopsies from humans with peripheral artery disease.

35 he most common presentation of infrainguinal peripheral artery disease.

36 ergic signaling in a cohort of patients with peripheral artery disease.

37 etes is a major risk factor for coronary and peripheral artery diseases.

38 ), persistent or recurrent manifestations of peripheral artery disease (22.2%), cardiac conditions (1

39 es were measured in 226 patients with stable peripheral artery disease admitted for nonurgent invasiv

40 Peripheral artery disease affects >200 million people wo

41 Atherosclerotic peripheral artery disease affects 8% to 12% of Americans

42 le disparities in stroke, heart failure, and peripheral artery disease among African Americans.

43 g, adjusted HR 5.76 [4.90-6.77] for incident peripheral artery disease and 10.61 [5.70-19.77] for amp

44 rterial studies investigated lower-extremity peripheral artery disease and acute stroke (35% and 24%,

45 ecently discovered therapeutic treatment for peripheral artery disease and critical limb ischemia.

46 nd organizations to advance the treatment of peripheral artery disease and critical limb ischemia.

47 lpha, improves walking time in patients with peripheral artery disease and intermittent claudication.

48 enase bright (ALDHbr) cells in patients with peripheral artery disease and to explore associated clau

49 onary heart disease, cerebrovascular events, peripheral artery disease, and congestive heart failure.

50 n and other coronary artery disease, stroke, peripheral artery disease, and congestive heart failure;

51 relative lymphocyte count, prothrombin time, peripheral artery disease, and contralateral carotid occ

52 ia for up to 24 hours in the murine model of peripheral artery disease, and doubled muscle perfusion

53 n off-loading, stimulation of wound healing, peripheral artery disease, and infection.

54 rce, heart failure, coronary artery disease, peripheral artery disease, antiphospholipid syndrome, an

55 Patients with peripheral artery disease are at risk of systemic athero

56 neuroischaemic if peripheral neuropathy and peripheral artery disease are both present.

57 , such as myocardial infarction, stroke, and peripheral artery disease, are the leading cause of morb

58 munity-based studies since 1997 that defined peripheral artery disease as an ankle brachial index (AB

59 her heart rate, prior myocardial infarction, peripheral artery disease, Asian race, male sex, and hig

60 ents, we analysed adult participants without peripheral artery disease at baseline at the individual

61 sed 817 084 individuals without a history of peripheral artery disease at baseline from 21 cohorts.

62 professionals and millions of patients with peripheral artery disease at the 2015 Centers for Medica

63 Older age, shorter height, ischemic cause, peripheral artery disease, atrial fibrillation, diabetes

64 anisms underlying the exercise impairment in peripheral artery disease based on an evaluation of the

65 es the first comparison of the prevalence of peripheral artery disease between high-income countries

66 atment of diabetic microvascular disease and peripheral artery disease but are hindered by the comple

67 emoral artery of a rat for 72 h, a model for peripheral artery disease, causes an exaggerated exercis

68 Future peripheral artery disease cell therapy investigational t

69 In the peripheral artery disease cohort, the primary end point

70 Conclusions and Relevance: Peripheral artery disease confers a poor prognosis in pa

71 The percutaneous therapies for peripheral artery disease continue to evolve with longer

72 Percutaneous therapies for peripheral artery disease continue to evolve with new te

73 chronic lung disease, age 75 years or older, peripheral artery disease, diabetes, tobacco use, white

74 red and fifty-five patients with symptomatic peripheral artery disease due to de novo superficial fem

75 diagnoses (coronary artery disease, stroke, peripheral artery disease, dysrhythmias, or heart failur

76 ith chronic kidney disease), and at least 50 peripheral artery disease events, we analysed adult part

77 Approximately one-third of patients with peripheral artery disease experience intermittent claudi

78 vascular perfusion is a hallmark feature of peripheral artery disease for which minimal therapeutic

79 May 10, 2016, we enrolled 7470 patients with peripheral artery disease from 558 centres.

80 ificantly improved stratification of AAA and peripheral artery disease groups when compared with trad

81 lled based on previous revascularization for peripheral artery disease had higher rates of myocardial

82 r V, a man with severe coronary, aortic, and peripheral artery disease, had an episode of brain ische

83 In the 21st century, peripheral artery disease has become a global problem.

84 rt-term reproducibility of this technique in peripheral artery disease has not been assessed, and the

85 Patients with peripheral artery disease have a marked reduction in exe

86 Patients with peripheral artery disease have an increased risk of card

87 Preliminary studies of antibiotic therapy in peripheral artery disease have shown a decreased need fo

88 rdial infarction, or stroke in patients with peripheral artery disease; however, vorapaxar significan

89 ER = $44,779/QALY gained), and patients with peripheral artery disease (ICER = $13,427/QALY gained).

90 lobally, 202 million people were living with peripheral artery disease in 2010, 69.7% of them in LMIC

91 C), establishes the primary risk factors for peripheral artery disease in these settings, and estimat

92 eview of the literature on the prevalence of peripheral artery disease in which we searched for commu

93 In patients with symptomatic peripheral artery disease, in comparison with LEB, PVI w

94 Treatment for symptomatic peripheral artery disease includes lower extremity bypas

95 d dipstick proteinuria with the incidence of peripheral artery disease (including hospitalisation wit

96 ceding decade the number of individuals with peripheral artery disease increased by 28.7% in LMIC and

97 ncluding hospitalisation with a diagnosis of peripheral artery disease, intermittent claudication, le

98 Peripheral artery disease is a potentially incapacitatin

99 Lower limb peripheral artery disease is a prevalent chronic non-com

100 These results also suggest that peripheral artery disease is associated with an inflamma

101 oral and popliteal arteries in patients with peripheral artery disease is compromised by restenosis a

102 Peripheral artery disease is considered to be a manifest

103 ents demonstrated among patients with stable peripheral artery disease is elevated after revasculariz

104 Lower extremity peripheral artery disease is the third leading cause of

105 mb ischemia (CLI), the most advanced form of peripheral artery disease, is associated with significan

106 amputation in patients with lower-extremity peripheral artery disease (LE PAD) during the study peri

107 diameter is associated with lower-extremity peripheral artery disease (LE-PAD).

108 thelial dysfunction present in patients with peripheral artery disease may be better understood by me

109 lled trial conducted among 212 patients with peripheral artery disease (mean age, 65.5 [SD, 6.2] year

110 ts with stable coronary, cerebrovascular, or peripheral artery disease (n = 15,264) had a lower risk

111 Patients with qualifying peripheral artery disease (n=3787) had a history of clau

112 We then used the risk factors to predict peripheral artery disease numbers in eight WHO regions (

113 ry heart disease, stroke, heart failure, and peripheral artery disease) occurred (236 events in subje

114 Eligible patients had a history of peripheral artery disease of the lower extremities (prev

115 balloons (DCBs) for treatment of symptomatic peripheral artery disease of the superficial femoral and

116 mia-reperfusion paradigm in 96 patients with peripheral artery disease of varying severity and 10 hea

117 tent claudication with objective evidence of peripheral artery disease), of the carotid arteries (pre

118 s (odds ratio [OR]: 1.27; p = 6.7 x 10(-4)), peripheral artery disease (OR: 1.47; p = 2.9 x 10(-14)),

119 ary artery disease, cerebrovascular disease, peripheral artery disease, or abdominal aortic aneurysm

120 scular disease [prior myocardial infarction, peripheral artery disease, or aortic plaque], age 65-75

121 scular disease [prior myocardial infarction, peripheral artery disease, or aortic plaque], age 65-75

122 nary artery diseases, heart failure, stroke, peripheral artery disease, or CVD-related mortality.

123 CVD events (coronary heart disease, stroke, peripheral artery disease, or heart failure).

124 myocardial infarction or stroke; the primary peripheral artery disease outcome was major adverse limb

125 ARAS was associated with peripheral artery disease (p = 0.004) and lower high-den

126 than in controls without clinically evident peripheral artery disease (P<0.0001).

127 cco use is an important preventable cause of peripheral artery disease (PAD) and a major determinant

128 about the prevalence of objectively assessed peripheral artery disease (PAD) and its clinical relevan

129 Patients with peripheral artery disease (PAD) are at heightened risk o

130 Patients with peripheral artery disease (PAD) are at heightened risk o

131 Patients with peripheral artery disease (PAD) are at high risk of card

132 New data on the epidemiology of peripheral artery disease (PAD) are available, and they

133 ospective data pertaining to MetS and future peripheral artery disease (PAD) are sparse, with few stu

134 lking ability in people with lower extremity peripheral artery disease (PAD) are unclear.

135 cy and safety of evolocumab in patients with peripheral artery disease (PAD) as well as the effect on

136 ioprotective medications in the treatment of peripheral artery disease (PAD) by socioeconomic status

137 The prevalence of peripheral artery disease (PAD) continues to increase wo

138 Peripheral artery disease (PAD) generates tissue ischemi

139 Many patients with peripheral artery disease (PAD) have walking impairment

140 Whether individuals with peripheral artery disease (PAD) identified by screening

141 To define how the incidence of peripheral artery disease (PAD) in chronic kidney diseas

142 mine whether there is a higher prevalence of peripheral artery disease (PAD) in individuals with lowe

143 se and lifestyle counseling in patients with peripheral artery disease (PAD) in the United States.

144 Peripheral artery disease (PAD) is associated with heigh

145 Peripheral artery disease (PAD) is associated with incre

146 Lower extremity peripheral artery disease (PAD) is frequently underdiagn

147 Screening for peripheral artery disease (PAD) may reduce morbidity and

148 reely perfused and ligated femoral arteries: peripheral artery disease (PAD) model.

149 t for claudication that is due to aortoiliac peripheral artery disease (PAD) often relies on stent re

150 ysis patients, but its effect on the risk of peripheral artery disease (PAD) remains unclear.

151 Patients with peripheral artery disease (PAD) show an exaggerated EPR,

152 t evidence to support advising patients with peripheral artery disease (PAD) to participate in a home

153 termine the association of family history of peripheral artery disease (PAD) with PAD prevalence and

154 by screening ankle brachial indices <0.9 for peripheral artery disease (PAD), and ultrasound imaging

155 shown by limb osteoporosis in patients with peripheral artery disease (PAD), but also could result f

156 ndividual clinical risk factors with risk of peripheral artery disease (PAD), but the combined effect

157 variance) to estimate prevalence ratios for peripheral artery disease (PAD), coronary artery calcifi

158 recommendations for secondary prevention in peripheral artery disease (PAD), the effect of aspirin i

159 Among persons with lower extremity peripheral artery disease (PAD), we determined whether o

160 effective treatment option for patients with peripheral artery disease (PAD).

161 long-term diabetes complications, including peripheral artery disease (PAD).

162 ngiogenic cytokine elevated in patients with peripheral artery disease (PAD).

163 ity among men and women with lower extremity peripheral artery disease (PAD).

164 oB) and lipoprotein (a) [Lp(a)], and risk of peripheral artery disease (PAD).

165 r challenge to intraluminal drug delivery in peripheral artery disease (PAD).

166 cular-weight (HMW) adiponectin, and incident peripheral artery disease (PAD).

167 cessation program designed for patients with peripheral artery disease (PAD).

168 e 6-minute walk performance in patients with peripheral artery disease (PAD).

169 cting the lower extremities is also known as peripheral artery disease (PAD).

170 or (VEGF) gene transfer for the treatment of peripheral artery disease (PAD).

171 rement in healthy subjects and subjects with peripheral artery disease (PAD).

172 d improving outcomes in patients with severe peripheral artery disease (PAD).

173 sed revascularization rates in patients with peripheral artery disease (PAD).

174 ve pulmonary disease (COPD; P=9.3 x 10(-4)), peripheral artery disease (PAD; P=0.090) and abdominal a

175 performance and daily ambulatory activity in peripheral artery disease patients with intermittent cla

176 ng patients with symptomatic femoropopliteal peripheral artery disease, percutaneous transluminal ang

177 Peripheral artery disease predicted moderate progression

178 nsion, diabetes, cardiovascular disease, and peripheral artery disease predicted severe progression o

179 o be older, female, and have higher rates of peripheral artery disease, prior stroke, and hypertensio

180 inergic signaling plays an important role in peripheral artery disease progression.

181 d estimates the number of people living with peripheral artery disease regionally and globally.

182 s without subsequent ST in the Excellence in Peripheral Artery Disease registry.

183 Ischemia, primarily caused by peripheral artery diseases, represents a major complicat

184 Peripheral artery disease results in atherosclerotic obs

185 data to support use of these therapies after peripheral artery disease revascularization exist, and m

186 Both eGFR and ACR significantly improved peripheral artery disease risk discrimination beyond tra

187 luminal balloon angioplasty in patients with peripheral artery disease Rutherford-Becker class 2 to 5

188 ry artery disease, congestive heart failure, peripheral artery disease, severe liver disease, diabete

189 induced ischemia are highly correlated with peripheral artery disease severity.

190 tention should be paid to the development of peripheral artery disease symptoms and signs in people w

191 ificantly lower in patients with symptomatic peripheral artery disease than in healthy volunteers.

192 ication is a common and disabling symptom of peripheral artery disease that can be treated with medic

193 Critical limb ischemia is a manifestation of peripheral artery disease that carries significant morta

194 proving collateral function in patients with peripheral artery disease, there is currently no method

195 In patients with symptomatic peripheral artery disease, ticagrelor was not shown to b

196 associated with 15 putative risk factors for peripheral artery disease to estimate their effect size

197 ndomly assigned 111 patients with aortoiliac peripheral artery disease to receive 1 of 3 treatments:

198 ly assigned 13,885 patients with symptomatic peripheral artery disease to receive monotherapy with ti

199 elor In PAD) randomized 13 885 patients with peripheral artery disease to treatment with ticagrelor 9

200 Evidence from large, randomized, controlled peripheral artery disease trials reporting long-term out

201 trial enrolled 264 patients with symptomatic peripheral artery disease undergoing percutaneous treatm

202 ard ratios (HRs) for incident study-specific peripheral artery disease was 1.22 (95% CI 1.14-1.30) at

203 the adjusted HR for incident study-specific peripheral artery disease was 1.50 (1.41-1.59) at an ACR

204 story of stroke, coronary artery disease, or peripheral artery disease were enrolled in a case-contro

205 patients with claudication and infrainguinal peripheral artery disease were randomized at 9 sites, of

206 butable to superficial femoral and popliteal peripheral artery disease were randomly assigned in a 2:

207 18 261 cases of peripheral artery disease were recorded during follow-up

208 ients with stable coronary artery disease or peripheral artery disease were recruited at 602 hospital

209 gina, stroke, transient ischemic attack, and peripheral artery disease, were adjudicated by committee

210 with intermittent claudication secondary to peripheral artery disease who were seropositive for C pn

211 In patients with symptomatic peripheral artery disease with a history of limb revascu

212 uality of life for symptomatic patients with peripheral artery disease with intermittent claudication

213 The treatment of peripheral artery disease with percutaneous transluminal

214 disease conferred increased risk of incident peripheral artery disease, with a strong association bet